Zydus Wellness is an Indian FMCG company with a dual engine: a domestic portfolio spanning seasonal health drinks (Glucon-D, Nycil), skin and hair care (Everyuth, Cuticolor), nutrition (Complan, RiteBite Max Protein, Sugar Free) and a fast-growing international digital wellness business, Comfort Click, acquired in late 2025. The company earns its money from brand-led consumer products with high gross margins; Q1 FY27 net sales reached INR 14,299 million, up 66.7% year on year, and EBITDA of INR 2,417 million translated to an EBITDA margin near 17% on a like-to-like basis. The competitive structure in its niches is favourable: Sugar Free leads the sweetener category, Everyuth leads in scrubs and peel-off masks, RiteBite is the only profitable protein snacking brand in its segment, and Complan holds a top-four share even as its core category degrows. Comfort Click operates in the European online VMS space with leading positions in five markets.
The persistence of these economics rests on strong brand equity, distribution depth, and a digital-first model that is difficult to replicate. Domestic brands have decades of trust, and the company has pivoted to organised channels, which reached 38% of sales in Q1 FY27 with modern trade at 17% and digital commerce at 21%. This channel shift improves margins and data-driven marketing. On the international side, Comfort Click's online-only model in the over-€11 billion European VMS market benefits from a structural shift to e-commerce; management noted a 31.4% like-for-like growth in international sales in Q4 FY26 and 29.5% for full-year FY26, with expansion into new markets and platforms. The barriers are the combination of brand recognition, regulatory hurdles in health products, and the scale of digital media investment required, which favours established players. The company also benefits from a 66-67% gross margin profile, which gives room to invest in A&P while still growing.
The inflection point is already underway: the acquisition of Comfort Click has shifted the mix from seasonal, weather-dependent domestic sales toward a diversified, internationally scaled portfolio. Management expects this business to remain EPS accretive and grow double digits, with launches on Walmart (US), Noon (UAE) and Boots.com (UK) and new product development. Domestically, RiteBite Max Protein is expanding beyond bars into RTD beverages and chips, Complan has launched Powerplay RTD and adult nutrition, and Glucon-D Recharge is targeting performance hydration. By the end of FY28 (18-24 months from now), the base business (ex-Comfort Click) should be generating EBITDA margins of 16-18% as per repeated management guidance, while Comfort Click itself is guided to maintain 14-15% EBITDA margin. This would lift consolidated margins from the current ~17% (which already includes Comfort Click) to a higher level, supported by operating leverage and mix. The seasonal drag from Nycil and Glucon-D, which declined 18.8% in FY26 due to weather, should normalise as management expects recovery from May 2026.
On walk-talk, management has consistently guided to 16-18% EBITDA margins for the base business over the next 1-2 years across calls in May 2026 and August 2026, but the delivery has been uneven. Q1 FY27 net profit fell 7% year on year due to amortisation of acquired brands and a higher effective tax rate near 27%, although excluding those items profit grew 26.5%. EBITDA grew 55.3% in Q1 FY27, but the margin expansion was modest on a like-for-like basis. The company did reduce interest costs by refinancing the acquisition debt from GBP to a lower-cost Euro facility, and Comfort Click became EPS accretive in Q4 FY26 as promised. The key promise, however, a 17-18% base EBITDA margin, remains unproven, with the timeline often described as 'next couple of years'; the latest extracted guidance reiterates 16-18% for base and 14-15% for Comfort Click in FY27.
The quantified earnings path depends on sustained double-digit growth from Comfort Click and a recovery in domestic seasonals. If international continues its ~30% growth and domestic non-seasonal brands maintain 15-20% growth, consolidated EBITDA could compound at a high-teens rate, with margin expansion adding another 200-300 basis points. The main falsifier is weather: another poor summer would delay the seasonal recovery and push the margin target out. Also, the US and UAE expansion for Comfort Click is still 'very small' and not yet material, so if that fails to scale, the growth algorithm weakens. The tension between rising EBITDA and falling PAT is an accounting artifact from amortisation and is not a sign of operational decay; cash flow is improving as deferred tax assets unwind. The critical watchpoint is the base EBITDA margin trajectory, which has slipped before; only when it consistently prints above 15% will the target be credible, and the next two quarters will be telling.
companyname: Zydus Wellness Limited ticker: ZYDUSWELL sector: Consumer Health & Wellness / FMCG Zydus Wellness is a diversified consumer health and wellness company that operates across three broad businesses: food & nutrition, personal care, and a fast-growing international vitamins, minerals and supplements (VMS) business. The company was established in 1988 and is part of the Zydus group. It listed on the NSE and BSE in 2005. The domestic business is built on a portfolio of iconic Indian br...
Read the full report →margin expansion, new product segment, geographic expansion
FY27 EBITDA margin guided at 14-15% for Comfort Click and 16-17% for base business driven by portfolio scale-up and margin expansion
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Zydus Wellness Limited and 4,900+ companies.
5-day free pass. No card required.